{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG001","OG002","OG003","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.009","statisticalMethod":"Cochran-Armitage trend test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"49"}],"units":"Participants"}],"description":"ACR70 responders were participants with at least 70% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS. Missing values were imputed using NRI, where non-responders were participants who discontinued the study prior to the completion of Part A. Percentage of participants achieving ACR70 response=(number of ACR70 responders / number of participants treated) \\* 100.","groups":[{"description":"Participants on background methotrexate therapy administered 1 x 1-mg baricitinib (LY3009104) capsule + 1 identical placebo capsule, orally once daily for 12 weeks.","id":"OG000","title":"1 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 2 x 1-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.","id":"OG001","title":"2 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 1 x 4-mg baricitinib (LY3009104) capsule +1 identical placebo capsule, orally once daily for 12 weeks.","id":"OG002","title":"4 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 2 x 4-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.","id":"OG003","title":"8 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 2 placebo capsules, orally once daily for 12 weeks.","id":"OG004","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"All participants who received any study drug in Part A.","reportingStatus":"POSTED","timeFrame":"Baseline up to 12 weeks","title":"Percentage of Participants Who Achieved an ACR70 Response at 12 Weeks (Part A)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}